Questions from Potential Applicants and CDC Responses

RFA-DP-23-004 *"Health Promotion and Disease Prevention Research Centers: 2023 Special Interest Project Competitive Supplement (SIPS)"*

SIP23-001 *"Effective Community Conversations for Influenza and COVID-19 Vaccine Uptake"*

Q1. We are writing to seek some clarification on the RFA-DP-23-004. Is the RFA asking for an evaluation of an existing community conversation intervention or research to inform the development of future community conversation interventions?

Response Q1: RFA DP-23-004 seeks research to inform the development of future community conversation interventions. While this can build on existing, funded community conversation interventions for understanding strengths/limitations of prior approaches – it seeks to fund new research to inform the development of future community conversation interventions.

Q2. I am writing a proposal for the SIP 23-001 on "Effective Conversations for Influenza and COVID-19 Vaccine Uptake". Please clarify if the expectation of this NOFO is a pilot intervention and analysis of effectiveness at getting people vaccinated or if it is more qualitative to inform the elements of such conversations? We keep going back and forth at the word "Effective" conversations and how much we can proof effectiveness in a period of one year. We will really appreciate any clarification you can provide about the expectations of the depth of the study design.

Response Q2: The objective of SIP23-001"Effective Conversations for Influenza and COVID-19 Vaccine Uptake" is to conduct an assessment of community-level vaccine conversations, the messengers, and training used. Applicants may utilize systematic qualitative and/or quantitative approaches to achieve the study objectives. Findings from this project will allow CDC to better tailor future project requirements when soliciting community partnerships in promoting vaccine uptake.

Q3: We have one question related to the announcement: Are applicants to identify and work with community partners who were funded through Partnering for Vaccine Equity (P4VE)?

Response Q3: Applicants may choose to partner or collaborate with many types of stakeholders and are not limited to P4VE-funded organizations. The NOFO provided some

examples in Section VIII, under “collaboration/partnerships” which included local government agencies, community health organizations and non-profit organizations.

Q4. Our Prevention Research Center is considering submitting an application to the above referenced NOFO [DP23-004]. Is it allowed or would it be considered favorably to submit an application in partnership with a PRC from another State?

Response Q4: Partnerships with other PRCs are not prohibited per Section VIII Other Information “collaboration/partnerships” in the NOFO; however, there is no additional scoring for multiple-PRC projects. Applicants should recruit as much academic/research expertise as needed to effectively implement the proposed project.